Rutgers Cancer Institute of New Jersey and RWJBarnabas Health today announced that data from SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL), and two abstracts from the neoadjuvant I-SPY 2 trial evaluating oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer, have been selected as late-breaking presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held both in person in Chicago and online from June 2-6. Read More
Steven K. Libutti, MD, FACS, Director, Rutgers Cancer Institute of New Jersey and Senior Vice President, Oncology Services, RWJBarnabas Health